FUTURELINK 2018

Serialisation legislation could improve recall process for drugmakers, says exec

By Flora Southey contact

- Last updated on GMT

Getty/vvs1976
Getty/vvs1976
Impending EU serialisation regulations could enhance drug recall procedures for pharmaceutical companies, says executive.

The EU Falsified Medicines Directive​ (FMD) – due to come into effect on February 9, 2019 – aims to prevent entry of falsified medicines into Europe’s pharmaceutical supply chain.

However, IBI-Lorenzini’s operations director Luca Pezzano said the Directive may also help pharmaceutical companies reconcile drugs in the event of a recall.

“Product reconciliation is one of the biggest issues a drugmaker faces during a product recall,” ​Pezzano told delegates at TraceLink’s FutureLink conference in Munich last week.

Knowing exactly where a product is – thanks to its attributed serial number – could improve the chances of reconciling 100% of a recalled drug product, he said.

Epista Life Science consultant Pasi Kemppainen, who is currently management advisor of serialisation and traceability at Santen Pharmaceutical, agreed the FMD could improve the recall process for marketing authorisation holders (MAHs).

“We also need to understand that it’s not only prescription drugs that are recalled. It’s also OTCs [over-the-counter drugs] and medical devices, so the recall procedures need to be basically the same for all the product categories,” ​he told delegates.

According to Kemppainen, serialisation data could also be used by drugmakers to analyse the recall, and improve its transparency.

In the case of a recall, Santen would “definitely” want to see the data to ensure all recalled products had been received by third-party logistics (3PL) partners, he added: “Patient safety must come first.”

Related news

Show more

Related products

show more

Transforming Clinical Development

Transforming Clinical Development

PerkinElmer | 01-Jun-2021 | Technical / White Paper

The estimated cost of bringing a drug to market in the U.S. according to JAMA is $1 billion.1 The extreme cost of clinical trials urge biopharmaceutical,...

Vaccine Innovation in the Era of COVID19

Vaccine Innovation in the Era of COVID19

Covance Patient Safety | 01-Oct-2020 | Sponsored Link

During this time of worldwide crisis, there is an increasing demand for the acceleration of a vaccination for COVID19. Regardless of the great recent advancements...

Strategies to Achieve Successful Approval & Launch

Strategies to Achieve Successful Approval & Launch

Catalent Pharma Solutions | 03-Sep-2020 | Data Sheet

There are several key considerations to how companies should approach commercial-scale manufacturing that may aid the success of their biologic’s launch...

Follow us

Products

View more

Webinars